IntegriChain Executive and Leadership Team

Joshua Halpern, the Co-Founder & Chief Executive Officer at IntegriChain, directs the overarching strategy and vision for the company's data and business process platform. Halpern guides the organization's mission to support therapy commercialization and market access for pharmaceutical manufacturers. This leadership involves defining the strategic roadmap for the ICyte Platform, ensuring its continued evolution to meet the demands of specialty and precision medicine. Overseeing the integration of financial, operational, and commercial data sets, Joshua Halpern ensures that pharmaceutical innovators can effectively digitalize their market access operations. The Chief Executive Officer's focus remains on empowering clients to make data-driven decisions, freeing up resources for critical business functions and ultimately driving market access success.

Matthew Heyman, the Chief Financial Officer at IntegriChain, directs the financial strategy and fiscal management of the company's data and business process platform for therapy commercialization. Heyman oversees all financial operations, including budgeting, forecasting, and resource allocation, ensuring the sustainable growth and profitability of IntegriChain. This critical role involves managing financial relationships with stakeholders and ensuring compliance with all regulatory requirements. The Chief Financial Officer's expertise is vital in supporting the company's mission to provide robust solutions for market access and therapy commercialization. Matthew Heyman ensures that the financial health of the organization enables continuous innovation and the effective delivery of the ICyte Platform to pharmaceutical manufacturers.

Sean Downey, the Chief Operating Officer at IntegriChain, manages the operational infrastructure and business process execution that underpins the company's therapy commercialization and market access solutions. Downey ensures the seamless delivery of services, optimizing the orchestration of commercial and government payer contracting, patient services, and distribution channels for pharmaceutical manufacturers. This leadership role involves driving operational efficiencies and ensuring the reliability of the ICyte Platform in unifying diverse data sets. The Chief Operating Officer's focus is on enhancing the client experience through streamlined processes and robust business practices. Sean Downey plays a critical part in enabling pharmaceutical innovators to digitalize their market access operations, ensuring that resources are effectively allocated to support data-driven decision-making and market penetration.

Bradley Burget, the Chief Technology Officer at IntegriChain, architects the technological foundation of the ICyte Platform, driving innovation in data and business process solutions for therapy commercialization. Burget oversees the development and implementation of advanced applications that unite critical financial, operational, and commercial data sets. This role is pivotal in ensuring the platform's scalability and security, supporting the complex needs of pharmaceutical manufacturers in the era of specialty and precision medicine. The Chief Technology Officer's responsibilities include leading the engineering teams, fostering a culture of technological excellence, and translating market demands into robust, cutting-edge software solutions. Bradley Burget ensures that IntegriChain's technology infrastructure empowers clients to digitalize market access operations effectively.